

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dean Engelhardt et al.
Serial No.: 08/486,069
Filed: June 7, 1995
For: NUCLEIC ACID SEQUENCING PROCESSES
USING NON-RADIOACTIVE MODIFIED OR LABELED
NUCLEOTIDES OR NUCLEOTIDE ANALOGS, AND
OTHER PROCESSES FOR NUCLEIC ACID DETECTION
AND CHROMOSOMAL CHARACTERIZATION USING
SUCH NON-RADIOACTIVE DETECTABLE MODIFIED
OR LABELED NUCLEOTIDES OR NUCLEOTIDE
ANALOGS (AS PREVIOUSLY AMENDED)

Group Art Unit: 1631
Ex'r: Ardin H. Marschel, Ph.D.

#58/W
Plunkett
(NE)
response to
non-comp. And,
needed first

527 Madison Avenue (9th Floor)
New York, New York 10022
March 12, 2001


FILED BY EXPRESS MAIL

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

COMMUNICATION FOR TRANSMITTING SECOND COMPOSITE CLAIM SET
(FOLLOWING APPLICANTS' MARCH 9, 2001
AMENDMENT UNDER 37 C.F.R. §1.115)

Dear Sirs:

This Communication follows Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115 which was in response to the January 30, 2001 Office Action issued in connection with the above-identified application. Because the purpose of this Communication is to transmit a composite claim set, which submission is within the three month period set forth in the January 30, 2001 Office Action, no extension request or fee is believed due in connection with this Communication.

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	EL839968874US
Deposit Date	March 12, 2001
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Ronald C. Fedus Reg. No. 32,567	MAR 12 2001 Date

Dean L. Engelhardt, II.
Serial No.: 08/486,069
Filed: June 7, 1995

Page 3 [Communication For Transmitting Second Composite Claim Set (Following Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115 (In Response To The January 30, 2001 Office Action)) - March 12, 2001]


SUMMARY AND CONCLUSIONS

Claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1727 continue to be presented for further examination in this application. No changes to the claims have been effected by this Communication.

No fee or fees are believed to be due in connection with this Communication. In the event that any other fee or fees are due, however, authorization is hereby given to charge the amount of any such fee(s) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the present application, Applicants' undersigned attorney request that he be contacted at the number provided below.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO DIAGNOSTICS, INC.
c/o ENZO BIOCHEM, INC.
527 Madison Avenue, 9th Floor
New York, New York 10022
Telephone: (212) 583-0100
Facsimile: (212) 583-0150

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Engelhardt et al.
 Serial No. 08/486,069
 Filed: June 7, 1995
 Type: **NP**
 Group Art Unit: 1631
 Examiner: Ardin H. Marschel, Ph.D.
NUCLEIC ACID SEQUENCING PROCESSES USING NON-RADIOACTIVE MODIFIED OR LABELED NUCLEOTIDES OR NUCLEOTIDE ANALOGS, AND OTHER PROCESSES FOR NUCLEIC ACID DETECTION AND CHROMOSOMAL CHARACTERIZATION USING SUCH NON-RADIOACTIVE MODIFIED NUCLEOTIDES OR NUCLEOTIDE ANALOGS (As Previously Amended)

FILED BY EXPRESS MAIL

Honorable Commissioner of
 Patents and Trademarks
 Washington, D. C. 20231

Sir:

Transmitted herewith is a Communication For Transmitting Second Composite Claim Set (Following Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115) in the above-identified patent application.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	1619	Minus	1619	= 0	X \$ 18	\$ 0
Indep	24	Minus	24	= 0	X \$ 80	\$ 0
()	First Presentation of Multiple Dependent Claims				+\$270	\$ 0
	TOTAL ADDITIONAL FEE					\$ 0


- () Charge Deposit Account No. 05-1135 in the amount of \$ _____.
- () A check in the amount of \$ _____ is attached.
- (X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135: any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.


Also enclosed: _____

March 12, 2001
 Date

Respectfully submitted,


 Ronald C. Fedus
 Registration No. 32,567
 Attorney for Applicant(s)

ENZO DIAGNOSTICS, INC.
 c/o Enzo Biochem, Inc.
 527 Madison Avenue (9th Fl.)
 New York, New York 10022
 Tel. (212) 583-0100
 Attorney's Docket No.: Enz-5(D8)(C2)

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No. EL839968874US	
Deposit Date March 12, 2001	
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Ronald C. Fedus Reg. No. 32,567	MAR 12 2001 Date

Enz-5(D8)(C2)